PRO
Marketplace
Seeking Alpha
Portfolio
People
News
Market News
On The Move
All Market News
Top News
Wall St. Breakfast
IPOs
US Economy
M&A
Cryptocurrency
News by Sector
Tech
Energy
Healthcare
Consumer
Financials
Commodities
Earnings
Earnings Calendar
Top Movers on Earnings
Earnings Analysis
Earnings News
Earnings Call Transcripts
Market Performance
Bonds
Commodities
Countries
Currencies
Dividends
Emerging Markets
Global and Regions
Growth & Value
Market Cap
Real Estate
Sectors
Strategies
Smart Beta
Subsectors
Analysis
Stock Ideas
Long Ideas
Short Ideas
Sectors
Editor's Picks
Quick Picks
Fund Letters
Dividends
REITs
Dividend Ideas
Dividend Strategy
Dividend News
Dividend Quick Picks
Editor's Picks
Market Outlook
Global Markets
Today's Market
Economy
Gold & Precious Metals
Commodities
Forex
Real Estate
Editor's Picks
Cryptocurrency
Investing Strategy
Portfolio Strategy
Fixed Income
Bonds
Financial Advisors
Retirement
IPOs
Editor's Picks
ETFs and Funds
ETF Screener
ETF Analysis
ETF Guide
Mutual Funds
Closed End Funds
Editor's Picks
Sign in / Join Now
ESALY
Eisai Co., Ltd. ADR |
OTCPK - Current
Analysis & News
Earnings
Dividends
StockTalk
Key Data
Financials
Transcripts
ESALY StockTalk
ESALY Blogs
Overview
SEC Filings
Historical Quotes
Splits
Income Statement
Balance Sheet
Cash Flow
1d
5d
1m
6m
1y
5y
10Y
Advanced Chart
52wk high:
73.37
52wk low:
49.86
EPS:
1.65
PE (ttm):
44.58
Div Rate (ttm):
1.24
Yield (ttm):
1.70%
Market Cap:
$21.01B
Volume:
Analysis
Related Analysis
Long Case
Short Case
Analysis
Eisai's Rollercoaster: Sepsis Drug Failure Overshadows Eventful Few Days
EP Vantage
•
Jan. 26, 2011
•
2 Comments
China Biotech Week in Review: Investors Drawn to China Pharma
ChinaBio Today
•
Jan. 23, 2011
Eisai's Oncology Drug Finally Gets Reviewed
Derek Lowe
•
Jun. 3, 2010
News
News Summaries
Dividend News
M&A News
Partner News
Transcripts & Slides
News
Oryzon Genomics commences mid-stage study of Alzheimer's candidate
SA News
•
Mon, May 14
•
4 Comments
Morphotek licenses ADC linker technology to Bliss Bio in China
SA News
•
Mon, Apr. 9
Oryzon Genomics on go with mid-stage study of Alzheimer's candidate ORY-2001
SA News
•
Wed, Apr. 4
•
6 Comments
Teva launches generic Aloxi in U.S.
SA News
•
Fri, Mar. 23
•
25 Comments
Eisai's Lenvima OK'd in Japan for liver cancer
SA News
•
Fri, Mar. 23
Eisai (ESALF) Investor Presentation - Slideshow
SA Transcripts
•
Mon, Mar. 12
Merck (MRK) Teams Up With Eisai (ESALY) To Commercialize Cancer Med Lenvima - Slideshow
SA Transcripts
•
Thu, Mar. 8
FDA issues draft industry guidance for early-stage Alzheimer's disease
SA News
•
Thu, Feb. 15
•
38 Comments
Eisai Co., Ltd. ADR 2017 Q2 - Results - Earnings Call Slides
SA Transcripts
•
Nov. 3, 2017
Eisai reports 1H results
SA News
•
Nov. 1, 2017
Eisai (ESALY) Present On Expanding Existing Collaboration With Biogen - Slideshow
SA Transcripts
•
Oct. 24, 2017
Eisai opts in to co-develop/co-promote Biogen's AD candidate aducanumab
SA News
•
Oct. 23, 2017
FDA accepts Eisai's marketing application for Lenvima for first-line liver cancer
SA News
•
Sep. 26, 2017
Eisai reports Q1 results
SA News
•
Aug. 2, 2017
Eisai Co. (ESALY) Investor Presentation - Slideshow
SA Transcripts
•
Mar. 10, 2017
Partner News
4 Paws for Ability Joins Eisai at 8th Annual National Walk for Epilepsy to Raise Awareness of the Benefits of Animal Assistance for People with Seizure Disorders
at CNBC.com (Mar 17, 2014)
